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Summary. Background: Clotting factor products have been
safe for HIV since 1985, and for hepatitis C since 1992. Few
studies have reported on mortality in the total population of
hemophilia patients after the period of risk of viral infection
transmission. Objectives: We studied the mortality, causes of
death, and life expectancy of hemophilia patients between
1992 and 2001. We compared these ﬁndings with those of
previous cohorts, together spanning the periods before,
during, and after the use of potentially contaminated clotting
products. Patients and methods: We performed a prospective
cohort study among 967 patients with hemophilia A and B.
Death rates, overall and cause-speciﬁc, were compared with
national mortality ﬁgures for males adjusted for age and
calendar period as standardized mortality ratio (SMRs).
Results: Between 1992 and 2001, 94 (9.7%) patients had died
and two patients were lost to follow-up (0.2%). Mortality
was 2.3-times higher in hemophilia patients than in the
general male population (SMR 2.3 95% conﬁdence interval
1.9–2.8). In patients with severe hemophilia, life expectancy
decreased from 63 (1972–1985) to 59 years (1992–2001).
Exclusion of virus-related deaths resulted in a life expectancy
at birth of 72 years. Conclusions: AIDS was the main cause
of death (26%) and 22% of deaths were because of hepatitis
C. In patients not aﬀected by viral infections, there still
appeared to be a trend toward a moderately increased
mortality compared with the Dutch male population. Thus,
mortality of patients with hemophilia is still increased; this is
largely because of the consequences of viral infections.
Keywords: hemophilia, life expectancy, mortality, viral infec-
tions.
Introduction
Hemophilia is an X-linked genetic bleeding disorder caused by
deﬁciency of coagulation factor VIII (FVIII) (hemophilia A) or
factor IX (FIX) (hemophilia B). Because of the hereditary
pattern of hemophilia, patients are almost invariably male,
while women can be carriers of the disease. Severe forms are
characterized by major bleeding occurring spontaneously or
after minor trauma. These hemorrhages often occur into joints
eventually causing the disabling arthropathy [1].
Before the introduction of clotting factor preparations, the
mean life expectancy of patients with hemophilia was
<30 years [2], and patients mostly died of intracranial or
other hemorrhages [3–5]. Since the 1960s, FVIII and FIX
preparations have been available for the treatment of hemo-
philia. This rapidly led to medical and social improvements,
with a decrease in the frequency of hemorrhages and
considerably improved life expectancy of patients with
hemophilia.
Despite these positive developments, mortality of patients
with hemophilia again increased during the 1980s. In 1982, the
ﬁrst case of acquired immunodeﬁciency syndrome (AIDS) in a
patient with hemophilia was reported [6,7]. Since then, many
more cases have been reported worldwide, of whommany have
died. In addition, about 80% of the patients treated with
clotting factor products before 1992 became infected with
hepatitis C [8,9]. The full consequences of hepatitis C infections
are only recently being recognized [10].
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Since 1985, virally safe [human immunodeﬁciency virus
(HIV)] products have been available and since 1992 virally safe
products for hepatitis C (HCV). Today, the most important
complication of clotting factor treatment is the development of
neutralizing antibodies (inhibitors) against FVIII or IX [11].
Few studies have reported on mortality in the total popula-
tion of hemophilia patients after the period of the risk of viral
infection transmission. Several studies have aimed at describing
mortality within a speciﬁc subpopulation, such as hemophilia
patients infected with HIV [12–14]. This study completes the
inventory of mortality in patients with hemophilia over the last
30 years in the Netherlands, and describes the period after the
use of potentially contaminated clotting products [15,16].
Objectives
We studied mortality, causes of death, and life expectancy of
hemophilia patients between 1992 and 2001. We compared
these ﬁndings with those of previous cohorts from our national
surveys on hemophilia, starting in 1972.
Material and methods
Study design
A prospective cohort study was performed as part of a survey
among all known patients with hemophilia in the Netherlands.
In June 1992, we sent questionnaires to all patients who were
listed with the Netherlands Hemophilia Society, with the
hemophilia treatment centers, or on the updated mailing lists
from previous surveys in 1972, 1978, and 1985 [17]. For this
national study, 1292 patients (93% of the total Dutch hemo-
philia population,n ¼ 1389)were sent aquestionnaireofwhom
967 (75%) responded. In total, 70% of all Dutch hemophilia
patients participated. Vital status at the end of study date was
determined by the response to the survey of 2001, from the
attending physician or frommunicipal population registries. Of
patients who had died during the follow-up, dates of deathwere
obtained frommunicipal registries and physicians. This study is
partof theHemophilia in theNetherlands (HIN-S study),which
has been approved by the Committee of Medical Ethics of the
Leiden University Medical Center.
Cause of death
The causes of death were obtained from the treating physicians
or general practitioners and were categorized according to the
10th revision of the International Classiﬁcation of Diseases,
Injuries, and Causes of Death-10 (ICD-10) [18]. Overall and
cause-speciﬁc mortality of the general Dutch male population
was retrieved from the Central Bureau of Statistics (CBS) [19].
Date of birth, severity of hemophilia, HIV status, and
information on inhibitory antibodies were derived from the
self-reported answers to the questionnaire. Severity of disease
and type of hemophilia were veriﬁed with the patients
physicians. Severity of hemophilia, depending on the residual
clotting factor activity was categorized as severe
(<0.01 IU mL)1 FVIII or FIX), moderate (0.01–
0.05 IU mL)1), or mild (>0.05–0.40 IU mL)1 FVIII or
FIX). The HIV status was based on the self-reported answers
of the patients. If patients were born after 1985 or if they
reported no treatment with the clotting factor between 1979
and 1985, HIV status was considered to be negative.
Statistical analysis
Indirect standardization Standardized mortality ratios
(SMRs) were calculated to estimate the rate of overall and
cause-speciﬁc death of patients with hemophilia relative to that
of the general male population adjusted for age and calendar
period. An SMR is the number of observed deaths divided by
the number that was expected if the mortality rate in the
cohort, with its speciﬁc age-distribution, was the same as that in
the general population. Patients were followed from 1 June
1992 to 1 July 2001. We used mortality rates from the Dutch
general male population between 1992 and 2001. Ninety-ﬁve
percent conﬁdence intervals (95% CI) were based on a
Poisson’s distribution for the observed number of deaths.
Cause-speciﬁc SMRswere calculated by studying the speciﬁc
cause of death as endpoint and censoring patients with other
endpoints.
Direct standardization In direct standardization, mortality
ratios are calculated by using an external standard as weight
factor. In our study, we used the WHO standardization weight
factors (http://www3.who.int/whosis/discussion_papers/pdf/
paper31.pdf). To put our ﬁndings into perspective mortality,
ﬁgures were comparedwith those of the previous cohort studies
between 1972–1985 (n ¼ 717) [15] and 1985–1992 (n ¼ 919)
[16].
Life expectancy Median life expectancy was calculated with
left truncated survival analysis andwas expressed as themedian
age at which cumulative survival was 50%. In a left truncated
survival analysis, patients are included in the analysis from the
start of the follow-up instead of data of birth.
Exclusion of viral infections Two methods were used to
exclude the effect of viral infections on mortality: (i) exclusion
of patients who reported to be HIV positive in 1992; and
(ii) censoring patients whose death was a result of HIV (AIDS)
or HCV (liver cirrhoses, hepatocellular carcinoma) at the date
of death.
Results
Table 1 shows the general characteristics of the patients with
hemophilia in 1992. Between 1992 and 2001, the total number
of patient-years of follow-up was 8868 [mean 8.6 (range 0–9)
years], 94 patients died and two patients were lost to follow-up.
Of all 967 patients in the cohort, 796 (87%) patients had
hemophilia A and 125 (13%) patients had hemophilia B; 386
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(39%) patients had severe hemophilia, 167 (17%) patients had
moderate hemophilia and 414 (43%) had mild hemophilia; the
mean age was 32 (range 0–82) years; 50 (5%) patients reported
having inhibitory antibodies against the deﬁcient clotting
factor; and 53 patients (6%) were HIV-positive. The mean
age at death was 52 years, with a range from 14 to 83 years.
The expected number of deaths during this same calendar
period was 39. The SMR was 2.3 (CI 1.9–2.8), indicating that
the overall mortality rate of patients with hemophilia was two
times higher than in the general male population. In patients
with severe hemophilia,mortality was ﬁve times higher than the
expected, SMR 5.1 (CI 3.8–6.8). Standardized mortality ratios,
taking into account HIV infection and severity of disease, are
shown in Table 2. Restriction of the analysis to HIV-negative
patients revealed thatmortality in patients with hemophilia was
70% higher than that in the general population (SMR 1.7, CI
1.3–2.7). After exclusion of deaths related to either HIV or
HCV, mortality rate among patients with hemophilia was 20%
higher than among the general population (SMR 1.2, CI 0.9–
1.6), in patients with severe hemophilia this was 40% (SMR
1.4, CI 0.8–2.4).
Direct standardization of mortality rates made compari-
sons between time periods possible. We found that mortality
of the whole cohort of patients with hemophilia did not
change over three time periods. Relative rate, compared with
subjects without hemophilia, i.e. the general population, was
1.6 between 1972 and 1985, 2.1 between 1985 and 1992 and
2.0 between 1992 and 2001. However, stratiﬁcation for
severity of hemophilia revealed that the rate of death of
patients with severe hemophilia might have increased over
the last 3 decades. It was 3-fold greater during the period
between 1985 and 1992, and it was 4.5-fold greater during
the last period of follow-up.
Table 1 General characteristics of participants at entry (1992)
n ¼ 967
Age (years) 32 (0–82)
Severity of disease
Severe (<0.01 IU ML)1) 386 (40)
Moderate (0.01–0.05 IU ML)1) 167 (17)
Mild (>0.05–0.40 IU ML)1) 414 (43)
Type of hemophilia
Hemophilia A 796 (87)
Hemophilia B 171 (13)
HIV infection 53 (6)
Inhibitor present* 50 (5)
Data presented are means (range) or numbers (percentages).
*Inhibitory antibodies against the deﬁcient clotting factor.
Table 2 Standardized mortality ratios (SMR) for severity and type of
hemophilia taking into account the HIV status
Observed
deaths*
SMR (95% CI)
All patients
HIV-negative
patients
All 94 2.3 (1.9–2.8) 1.7 (1.3–2.1)
Severity
Severe 47 5.1 (3.8–6.8) 2.8 (1.9–4.2)
Moderate 15 2.6 (1.5–4.3) 2.3 (1.3–3.9)
Mild 32 1.3 (0.9–1.9) 1.2 (0.8–1.6)
Type of hemophilia
Hemophilia A 81 2.3 (1.9–2.9) 1.7 (1.4–2.2)
Hemophilia B 13 2.3 (1.3–4.0) 1.3 (0.6–2.7)
*Data presented are absolute numbers of observed deaths.
95% conﬁdence interval.
Only including patients who reported to be HIV-negative or patients
who were born after 1985.
Table 3 Primary causes of death according to the ICD-10 classiﬁcation
Cause of death (ICD-10* Code)
1973–1986
n ¼ 43 (%)
1986–1992
n ¼ 45 (%)
1992–2001
n ¼ 94 (%)
AIDS (B20–34) 0 (0) 12 (27) 24 (26)
Hepatitis C 21 (22)
Hepatocellular carcinoma (C22) 5 (5)
Chronic liver disease (K70, K72.9, K73–K74, and C78.7) 0 (0) 5 (11) 10 (11)§
Diseases of the circulatory system (I00–I99) 4 (9) 10 (24) 16 (17)
Ischemic heart disease (I200–I25) 1 (2) 0 (0) 6 (6)
Cerebrovascular disease (I60–I69) 3 (7) 9 (20) 4 (5)#
Malignancies (C00–D48) 13 (30) 7 (15) 12 (15)
Hemorrhages 20 (47) 1 (2) 9 (10)
Caused by trauma (T14.9) 4 (4)
Other (A40.3, A41.9, J18, R06.8, and R54) or not natural cause of death (V01–Y98) 3 (5) 6 (9) 9 (10)–
Sudden death, cause unknown (R96, R99)** 3 (7) 4 (9) 3 (3)
*ICD-10, international classiﬁcation of diseases, 10th revision.
AIDS, acquired immunodeﬁciency syndrome.
Two patients died because of complications of liver transplantation, ﬁve of hepatocellular carcinoma, 10 of chronic liver disease, in four patients
only hepatitis C mentioned as cause of death.
§In four patients, a hemorrhagic shock was reported.
#All deaths because of hemorrhagic stroke.
–Trauma, pneumonia or septic shock, murder, suicide, and old age.
**One patient died from natural causes.
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Cause-specific mortality
Table 3 shows the primary causes of death between 1992 and
2001. Between 1992 and 2001, 24 (26%) patients died of AIDS
of whom 22 (87.5%) had severe hemophilia. In 21 patients
(22%), death was because of a HCV infection; in two of these
patients, complications of a liver transplantation were the cause
of death, while in ﬁve patients a hepatocellular carcinoma or
metastasis of a liver carcinoma was reported. Death because of
chronic liver disease was reported in 10 patients of whom ﬁve
died of a hemorrhagic shock. In four patients, only hepatitis C
was mentioned as cause of death. A co-infection with HIV and
HCVwas observed in ﬁve of the deaths resulting from hepatitis
C. Mortality of AIDS and chronic liver disease was highest in
patients with severe hemophilia although these causes of deaths
were also observed in four patients (27%) with moderate
hemophilia. Among patients in which death was not related to
HCV or HIV (n ¼ 49), the main cause of death was
hemorrhage (13/49, 27%), which also includes intracranial
hemorrhages (n ¼ 4) and hemorrhages resulting from trauma
(n ¼ 4). Compared with the Dutch male population, the
incidence of death from intracranial hemorrhages is higher in
patients with hemophilia, 0.1 per 1000 person-years and 0.5 per
1000 person-years (5/8868 person-years), respectively. Death
frommalignant neoplasm (including hepatocellular carcinoma)
was reported in 22% of patients. Although the percentage of
patients with mild hemophilia that died as a result of
malignancies was increased compared with the Dutch male
population, at 41% vs. 31%, overall mortality of malignancies
was decreased, at 19%vs. 31%.Death because of disease of the
circulatory system, including ischemic heart disease and
cerebrovascular disease, was lower in patients with hemophilia
than in theDutchmale population 17% and 28%, respectively.
Myocardial infarction (n ¼ 4) and cardiac arrest (n ¼ 3) were
the most prevalent ischemic heart disease. The cause of death
remained unknown in two patients.
In 20% (n ¼ 20) of deceased patients, the presence of an
inhibitor was reported at the time of death. In these patients,
either AIDS (n ¼ 11) or carcinoma (n ¼ 4) was the main cause
of death. Hemorrhage or hemorrhage-related deaths were
reported in three patients (including one intracranial death).
The proportion of patients that died of AIDS stayed
constant during the last two periods of follow-up. Death
because of hepatitis C increased compared with the period
between 1985 and 1992, 11% vs. 22%. No deaths of AIDS or
hepatitis C were reported in the ﬁrst period of follow-up (1972–
1985). The occurrence of cerebral vascular disease was lower
than in 1986–1992, when it accounted for 20% of all deaths
compared with 4% in the current period of follow-up.
In Table 4, cause-speciﬁc SMRs are shown. Mortality
because of AIDS infections was 117 times higher than in the
general population, and mortality because of HCV was 16
times (SMR 16.2, CI 7.7–33.8) higher in patients with
hemophilia than in the general population.
Life expectancy
Life expectancy was calculated and stratiﬁed for severity of
hemophilia and based on the extrapolation from the observed
death rates (Table 5). In patients with severe hemophilia, a life
expectancy of 59 years at birth was observed, and censoring of
Table 4 Primary cause of death-speciﬁc SMRs
Cause of death (ICD-10 Code) Observed* SMR (95 CI)
AIDS (B20–B24) 24 117.2 (77–178)
Hepatitis C
Hepatocellular
carcinoma (C22)
5 17.2 (5.2–35.9)
Chronic liver disease
(K70, K72.9, and K73–K74)
10 16.1 (7.7–33.8)
Ischemic heart disease (I20–125) 6 0.5 (0.2–1.1)
Cerebrovascular disease (I60–I69) 4 1.0 (0.2–2.2)
Malignancies 18 1.5 (1.0–2.5)
Malignancies (no liver) 12 1.1 (0.6–1.9)
*Absolute numbers of death observed.
95% conﬁdence interval.
Table 5 Life expectancy (years) according to severity in 30 years of follow-up
1972–1985 1985–1992
1992–2001
All
patients
(n ¼ 967)
HIV
negative*
(n ¼ 511)
HIV and HCV
negative
(n ¼ 967)
All patients (years) 66 68 67 70 74
Dutch males 71 74 76 76 76
Severity of hemophilia (IU mL)1)
Severe (<0.01) 63 61 59 70 71
Moderate (0.01–0.05) 65 65 67 71 75
Mild (>0.05–0.40) – 74 73 73 75
Type
Hemophilia A – 69 68 70 73
Hemophilia B – 64 60 73
*Patients of whom HIV status was negative or who were born after 1985.
HIV- and HCV-related deaths were censored; in this analysis, patients were not considered to be dead but lost to follow-up. Therefore, no patients
were excluded.
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patients who died because of virus infections resulted in a life
expectancy of 71 years in patients with severe and moderate
hemophilia. Life expectancy at birth of patients with mild
hemophilia was lower than that of the male population, at
73 years compared with 76 years. After censoring deaths
because of viral infections, the life expectancy of mild
hemophilia patients was 75 years.
The overall life expectancy of the patients with hemophilia
did not notably change between 1972 and 2001. The life
expectancy of patients with severe hemophilia, however,
decreased from 63 in the period between 1972 and 1985 to
59 years during the follow-up between 1992 and 2001. For
patients with moderate hemophilia, life expectancy increased
from 65 to 67 years.
Discussion
During the last decade, hemophilia was characterized by an
excess mortality when compared with the general population.
HIV infection was responsible for the largest number of deaths
(n ¼ 24, 26% of deaths) and 16% of deaths were because of
hepatocellular carcinoma or chronic liver disease (n ¼ 15)
resulting from a HCV infection. Overall, patients with severe
hemophilia had a 5-fold higher risk of death than men in the
general population. Without the effects of HIV and HCV, the
rate of death among patients with severe hemophilia was 1.4-
fold higher than expected. The remaining excess risk in all
likelihood results from hemorrhages. Life expectancy of
patients with severe hemophilia decreased compared with the
earlier studies, mostly inﬂuenced by HIV. Patients with severe
hemophilia not affected by hepatitis C or HIV had a life
expectancy of 71 years, which can be compared with a life
expectancy of the Dutch male population of 76 years.
In the survey of 1992, 93% of all Dutch hemophilia patients
were sent a questionnaire, of whom 75% participated in the
survey, and were subsequently followed for this study on
mortality. Only two patients were lost to follow-up and we
were able to retrieve 96%of all causes of death. This resulted in
a complete cohort comprising a large population of hemophilia
patients. There was no difference in severity of hemophilia or
mean age between the responding and non-responding popu-
lation to the questionnaire of 1992 and therefore we consider
our data to be generalizable to the Dutch hemophilia
population. Differences may exist between the responding
and the non-responding population in the rates of HIV or
hepatitis C. We cannot predict in which direction this might
have inﬂuenced our results: either patients with HIV or
hepatitis C are too ill to participate, which might lead to an
underestimation of mortality, or are more willing to participate
because of their disease. Theoretically, because the causes of
death were reported by the treating hematologist or the general
practitioner, there may have been discrepancies with the
general population data gathered through the CBS. In some
cases, the treating hematologists and general practitioners were
present at time of death and informed the CBS on the cause of
death, in other patients the physician present at the time of
death informed both the treating hematologist and the CBS.
Therefore, we do not expect this to be of large inﬂuence. As
always in research on life expectancy, the ﬁndings may not hold
for the present patients with hemophilia. Exclusion of effects of
viral infections results in a reﬂection of the current situation for
patients who have not been exposed to virally non-safe clotting
products. In our cohort, no deaths were reported in the
youngest age-category between 0 and 10 years. The youngest
participant to this study was 4 months old, and therefore our
study did not cover perinatal mortality. Because of the limited
information on the presence of inhibitory antibodies, we have
not been able to study the impact on mortality.
Our study shows a 2-fold increased mortality for patients
with hemophilia; in patients with severe hemophilia, this was
even a 5-fold increase. We estimated the future mortality
patterns in patients with hemophilia by excluding the death
because of HIV or hepatitis C as these infections will not likely
impact on the future mortality of patients with hemophilia.
Although not statistically signiﬁcant, there still appeared to be
a trend toward a moderately but enduring increased mortality
for patients with hemophilia, especially in severe hemophilia.
As nowadays products are safe from transmission of HIV and
hepatitis C, preventive efforts should focus on factors causing
this remaining excess mortality. The most important factor is
an increased risk of death of hemorrhages, either intracranial or
resulting from trauma. Althoughmortality of HCV andHIV is
extensive and the numbers for comparison with the general
population are limited, there seems to be a higher incidence of
death from intracranial hemorrhages in patients with severe,
moderate, and mild hemophilia. This indicates the importance
of adequate and specialized care for hemophilia patients.
Although we also observed a high number of other hemor-
rhages, for example resulting from trauma, we were not able to
make a comparison with the general population. A second
factor of impact could be deaths from hepatitis C that had not
been reported as such. However, as the hepatitis C status is well
known and a good registration is used by treating physicians,
this is probably of limited inﬂuence.
Over the last 3 decades, causes of death of patients with
hemophilia have changed; during the 1970s and early 1980s
patients with hemophilia died mostly of intracranial hemor-
rhages, while during the late 1980s AIDS became the main
cause of death. Although in the Netherlands the impact of
HIV was relatively low through the predominant use of
products from local voluntary unpaid donors, AIDS was
responsible for a quarter of all deaths during the 1990s. In the
present follow-up period, about 80% of deaths from AIDS
occurred before 1995, indicating that the impact of AIDS on
mortality of patients with hemophilia is declining. This
decreased inﬂuence is explained by a reduced number of
survivors of HIV infection, and by improved survival of
patients contaminated with HIV through highly active anti-
retroviral therapy (HAART) therapy [20]. The effects of
hepatitis C infections on mortality have increased considerably
during the last 10 years, and about 20% of deaths were
because of the effects of hepatitis C, of which liver cirrhosis or
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liver failure were the most prevalent. Our study shows a highly
increased risk of death of hepatocellular carcinoma, which is
similar to a study by Darby et al. [21] in which a 20-fold
increased risk was reported in non-HIV infected patients with
severe hemophilia. Although the introduction of new treat-
ment methods combining PEG-interferon with ribavirin will
positively inﬂuence the mortality of HCV-infected patients,
the effects of HCV will remain in those patients in whom this
therapy failed. For patients not affected by viral infections,
hemorrhage was still a relatively frequent cause of death. As
this is similar to the period before the impact of viruses
transmitted by clotting products, we might conclude that the
increased availability of clotting factor has not reduced the
number of deaths because of hemorrhages. The number of
deaths from malignant neoplasm was not higher than the
expected in this population. In concordance with earlier
studies and ﬁndings by Rosendaal et al. [22], we observed a
reduced rate of mortality of ischemic heart disease in patients
with hemophilia.
Life expectancy of patients with severe hemophilia was lower
during the last decade when compared with earlier observa-
tions. An important part of this decline is explained by death
because of viral infections. When AIDS and hepatitis C deaths
were excluded, life expectancy improved but although the
general life expectancy in European countries is approached, it
remains to be lower especially in patients with severe hemo-
philia [23].Walker et al. [24] published the same observations in
a Canadian population. After exclusion of viral infections
patients with mild and moderate hemophilia have a life
expectancy that is about equal to the average Dutch male
population.
Our data show that HIV and hepatitis C still largely
inﬂuence mortality of hemophilia patients. The effects of
hepatitis C will be present for many years to come. In patients
with severe hemophilia not infected with viruses, mortality is
still 40% higher when compared with the general population.
Although this suggests that the current patient with hemophilia
beneﬁts from safe clotting products, life expectancy is still
negatively inﬂuenced by this bleeding tendency.
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